-
公开(公告)号：US20170000803A1
公开(公告)日：2017-01-05
申请号：US15257727
申请日：2016-09-06
申请人： TherapeuticsMD, Inc.
CPC分类号： A61K31/57 , A61K9/4825 , A61K9/4858 , A61K47/14
摘要： This disclosure provides progesterone formulations, methods of using these formulations, and their related pharmacokinetic parameters. In particular embodiments, the formulations disclosed herein allow for a reduction in the amount of progesterone administered to a patient in need thereof, while still providing the benefits of a larger dosage amount.
摘要翻译： 该公开内容提供孕酮制剂，使用这些制剂的方法及其相关的药代动力学参数。 在具体实施方案中，本文公开的制剂允许减少施用于有需要的患者的孕酮的量，同时仍然提供更大剂量的益处。
-
公开(公告)号：US20150342963A1
公开(公告)日：2015-12-03
申请号：US14719933
申请日：2015-05-22
申请人： TherapeuticsMD, Inc.
IPC分类号： A61K31/57 , A61K9/10 , A61K31/565
CPC分类号： A61K31/565 , A61K9/10 , A61K9/4858 , A61K31/57 , A61K2300/00
摘要： Pharmaceutical compositions for co-administering estradiol and progesterone to a human subject in need thereof are provided. In some embodiments, the pharmaceutical composition comprises solubilized estradiol, suspended progesterone, and a solubilizing agent comprising a medium chain (C6-C12) oil.
摘要翻译： 提供了将雌二醇和孕酮共同施用于有需要的人类受试者的药物组合物。 在一些实施方案中，药物组合物包含溶解的雌二醇，悬浮的孕酮和包含中链（C6-C12）油的增溶剂。
-
公开(公告)号：US20130338122A1
公开(公告)日：2013-12-19
申请号：US13843362
申请日：2013-03-15
申请人： THERAPEUTICSMD, INC.
IPC分类号： A61K31/573 , A61K9/00 , A61K31/566
CPC分类号： A61K47/14 , A61K9/0014 , A61K9/1075 , A61K9/48 , A61K9/4825 , A61K31/565 , A61K31/566 , A61K31/57 , A61K31/573 , A61K45/06 , A61K47/10 , A61K2300/00
摘要： Hormone replacement therapies are provided comprising solubilized progesterone alone and optionally with an estrogen, cyclic/sequential and continuous-combined dosing, and administered via transdermal HRT delivery systems.
摘要翻译： 提供激素替代疗法，其包括单独的溶解的孕酮和任选的雌激素，循环/顺序和连续组合给药，并通过经皮HRT递送系统施用。
-
公开(公告)号：US20140100206A1
公开(公告)日：2014-04-10
申请号：US14099623
申请日：2013-12-06
申请人： TherapeuticsMD, Inc.
IPC分类号： A61K31/57 , A61K31/565
CPC分类号： A61K31/57 , A61K9/0034 , A61K9/02 , A61K9/1075 , A61K9/48 , A61K9/4858 , A61K9/4866 , A61K31/565 , A61K47/10 , A61K47/14 , A61K47/44 , A61K2300/00
摘要： Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.
-
公开(公告)号：US20140100205A1
公开(公告)日：2014-04-10
申请号：US14099612
申请日：2013-12-06
申请人： TherapeuticsMD, Inc.
IPC分类号： A61K31/57 , A61K31/565
CPC分类号： A61K31/57 , A61K9/0034 , A61K9/02 , A61K9/1075 , A61K9/48 , A61K9/4858 , A61K9/4866 , A61K31/565 , A61K47/10 , A61K47/14 , A61K47/44 , A61K2300/00
摘要： Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.
-
公开(公告)号：US20130338123A1
公开(公告)日：2013-12-19
申请号：US13843428
申请日：2013-03-15
申请人： THERAPEUTICSMD, INC.
IPC分类号： A61K31/57 , A61K47/44 , A61K31/565
CPC分类号： A61K31/57 , A61K9/0034 , A61K9/02 , A61K9/1075 , A61K9/48 , A61K9/4858 , A61K9/4866 , A61K31/565 , A61K47/10 , A61K47/14 , A61K47/44 , A61K2300/00
摘要： Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.
-
公开(公告)号：US20240115584A1
公开(公告)日：2024-04-11
申请号：US18468665
申请日：2023-09-15
申请人： TherapeuticsMD, Inc.
发明人： Brian A. Bernick , Janice Louise Cacace , Peter H.R. Persicaner , Neda Irani , Julia M. Amadio , Frederick D. Sancilio
CPC分类号： A61K31/57 , A61K9/1075 , A61K9/16 , A61K9/48 , A61K9/4825 , A61K9/4858 , A61K9/7023 , A61K31/565 , A61K47/10 , A61K47/14
摘要： Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.
-
公开(公告)号：US11497709B2
公开(公告)日：2022-11-15
申请号：US16834780
申请日：2020-03-30
申请人： TherapeuticsMD, Inc.
摘要： According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided. In various embodiments, such compositions are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.
-
公开(公告)号：US20200323881A1
公开(公告)日：2020-10-15
申请号：US16912665
申请日：2020-06-25
申请人： THERAPEUTICSMD, INC.
发明人： Brian A. Bernick , Julia M. Amadio , Peter H.R. Persicaner , Thorsteinn Thorsteinsson , Janice Louise Cacace , Frederick D. Sancilio , Neda Irani
IPC分类号： A61K31/57 , A61K31/565 , A61K47/44 , A61K47/10 , A61K47/14 , A61K9/107 , A61K9/48 , A61K9/00 , A61K9/02
摘要： According to various embodiments of this disclosure, pharmaceutical formulations comprising solubilized estradiol are provided. In various embodiments, such formulations are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.
-
公开(公告)号：US20170340739A1
公开(公告)日：2017-11-30
申请号：US15454898
申请日：2017-03-09
申请人： TherapeuticsMD, Inc.
发明人： Janice Cacace , Peter H.R. Persicaner , Thorsteinn Thorsteinsson , Frederick Sancilio , Julia Amadio , Brian Bernick
摘要： This disclosure provides progesterone formulations, methods of using these formulations, and their related pharmacokinetic parameters. In particular embodiments, the formulations disclosed herein allow for a reduction in the amount of progesterone administered to a patient in need thereof, while still providing the benefits of a larger dosage amount.
-
-
-
-
-
-
-
-
-
搜索结果
35 条记录 (耗时 0.029 秒)
